Investor Overview

Stock Information
Loading data...
Press Releases
Sep 16, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that seven data sets from clinical trials of Phexxi® (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at...

Sep 9, 2021

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of...

Sep 1, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows:...

Aug 11, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2021. "We are pleased to show strong and...

Jul 28, 2021

Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on Wednesday,...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The Company is evaluating its investigational drug candidate EVO100 for the prevention of chlamydia and gonorrhea in women in a pivotal Phase 3 clinical trial, EVOGUARD. Top-line results are expected in mid-2022 and assuming positive results Evofem plans to file an sNDA in the fourth quarter of 2022.

The addressable U.S. market opportunity for these current and investigational indications is estimated at $3.6 - $4.5 billion in aggregate.  

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. Discussions are underway with potential licensees for commercialization of Phexxi in multiple international markets.

Featured Event
Monday, September 13, 2021 - Wednesday, October 13, 2021
07:00 am EDT

Tune in to CEO Saundra Pelletier's presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available for on-demand listening after 7 a.m. ET on Monday September 13, 2021....

View All

Latest Financial Results

Q2 2021, Ended August 11, 2021

Earnings Release
Earnings Call
10-Q Filing